Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site Porto Alegre, Rio Grande do Sul, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Villejuif, France
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Madison, Wisconsin, United States
View all 19 locations
View Trial Details
Active, Not Recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hosptial Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Madison, Wisconsin, United States
  • GSK Investigational Site Fitzroy, Victoria, Australia
  • GSK Investigational Site Melbourne, Victoria, Australia
View Trial Details
Active, Not Recruiting

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

NCT04555551

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

NCT03556332

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, Not Recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Research Site Santa Barbara, California, United States
  • Research Site Aurora, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Minneapolis, Minnesota, United States
View all 38 locations
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

NCT07150091

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site São Paulo, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
View Trial Details

Related conditions